Stay updated with breaking news from Bronchiectasis Remains. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net...
—ARIKAYCE® Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022— —Company...
-- ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since...